DQWS.OIDDswiss INC

10-Q: DSwiss, Inc. Reports Strong Revenue Growth in Q1 2025, Despite Net Profit Decline

Sentiment:

Quarterly Report (Form 10-Q)


DSwiss, Inc. saw a significant increase in revenue for the three months ended March 31, 2025, but experienced a decrease in net profit compared to the same period in the previous year.

Worse than expectedNet income decreased from $177,665 to $138,736 year-over-year.Gross profit was slightly lower than the same period last year due to higher cost of revenue.Net cash used in operating activities was $84,751, compared to net cash generated of $62,517 in the prior year.

Summary

  • DSwiss, Inc. reported its financial results for the quarter ended March 31, 2025.
  • The company's revenue increased to $1,001,186 from $471,377 in the same period last year.
  • Gross profit was $263,047, slightly lower than the $269,885 reported in Q1 2024.
  • Net income decreased to $138,736 from $177,665 year-over-year.
  • The company's cash and cash equivalents totaled $304,637 as of March 31, 2025.
  • Net cash used in operating activities was $84,751, compared to net cash generated of $62,517 in the prior year.
  • The company identified material weaknesses in its internal control over financial reporting.

Sentiment

Score: 5

Explanation: The document presents mixed signals. Revenue growth is positive, but declining profits and identified internal control weaknesses temper the outlook. The company's reliance on future financing adds uncertainty.

Positives

  • The company experienced a substantial increase in revenue, more than doubling year-over-year.
  • The company is expanding its client base in OEM/ODM services.
  • DSwiss has a strong relationship with new retail tech companies.
  • The company plans to expand globally through strategic partnerships.

Negatives

  • Net profit decreased compared to the same period last year.
  • The company experienced negative operating cash flow.
  • Material weaknesses were identified in internal control over financial reporting.
  • Gross profit was slightly lower than the same period last year due to higher cost of revenue.

Risks

  • The company's ability to continue as a going concern is dependent on improving profitability and financial support from shareholders.
  • The company has material weaknesses in internal control over financial reporting.
  • Fluctuations in exchange rates could impact the company's income.
  • The company is exposed to credit risk related to accounts receivable.
  • The company relies on social media marketing, which could be affected by changes in social media platforms or user behavior.

Future Outlook

The company expects its current capital resources to meet its basic operating requirements for approximately twelve months and plans to grow through social media marketing and strategic partnerships.

Management Comments

  • Management believes the existing shareholders or external financing will provide the additional cash to meet the Company's obligations as they become due.
  • The feedback we have received from our clients has been overwhelmingly positive, which has helped us to create a robust brand image.

Industry Context

The company operates in the biotech-nutraceutical, beauty supplies, and medical consumables industries, focusing on OEM/ODM services. The company is expanding its client base in OEM/ODM services and has developed products and Business-to-business (B2B) DNA genotyping private label services that exceed the clients expectation.

Comparison to Industry Standards

  • It is difficult to compare DSwiss directly to industry standards without knowing specific competitors and their financial results.
  • However, the company's focus on OEM/ODM services is a common strategy in the nutraceutical and skincare industries.
  • Many companies in these sectors also utilize social media marketing to reach customers and build brand awareness.
  • The company's emphasis on certifications and approvals from the Ministry of Health (MOH) Malaysia aligns with industry best practices for ensuring product quality and safety.

Related Party Transactions

  • Professional fees paid to a related party A totaled $4,292 for the period ended March 31, 2025.
  • Sales to a related party B amounted to $1,284 for the period ended March 31, 2025.

Stakeholder Impact

  • Shareholders may be concerned about the decline in net profit and the identified material weaknesses in internal control.
  • Employees may be affected by potential changes in operations or financial stability.
  • Customers may be impacted by the company's ability to maintain product quality and availability.
  • Suppliers may be affected by the company's financial performance and ability to meet its obligations.
  • Creditors may be concerned about the company's negative operating cash flow and reliance on future financing.

Next Steps

  • The company plans to implement its social media marketing strategy.
  • The company intends to form partnerships with local companies in various countries to expand globally.
  • The company needs to address the identified material weaknesses in internal control over financial reporting.

Key Dates

DateDescription
2011-03-10DSwiss Sdn Bhd incorporated in Malaysia
2015-05-28DSwiss, Inc. incorporated in Nevada
2015-05-28DSwiss Holding Limited incorporated in Seychelles
2016-03-17DSwiss Biotech Sdn Bhd incorporated in Malaysia
2016-07-20Date of Form S-1 Amendment No.8
2018-07-30FASB issued ASU 2018-11
2018-07-31First finance lease agreement commenced
2019-01-01DSwiss officially adopted ASC 842
2019-11-01Effective date of ASC 842, Leases
2020Expanded client base in OEM/ODM services
2021-12-03Second finance lease agreement commenced
2022-12-31Date mentioned in relation to financial statements
2023-01-17Date mentioned in relation to DSwiss Biotech Sdn Bhd Member DQWS:DSwissHKLimitedMember
2023-01-18DSwiss (HK) Limited acquired 60% equity interest in DSwiss Biotech Sdn. Bhd.
2023-12-31Balance as of December 31, 2023 (audited)
2023-12FASB issued ASU 2023-09
2023-11FASB issued ASU 2023-07
2024-01-01Start of comparative period for financial results
2024-03-31End of comparative period for financial results
2024-11FASB issued ASU 2024-03
2024-12-21Third finance lease agreement commenced
2024-12-31Year ended December 31, 2024
2025-01-01Start of current reporting period
2025-01FASB clarified the effective date in January 2025 with the issuance of ASU 2025-01
2025-01-02DSwiss Sdn Bhd entered into a contract rental agreement
2025-03-01Commencement date of office rental agreement
2025-03-31End of current reporting period
2025-05-15Date of report filing
2025-06Due date of first finance lease agreement
2025-11Due date of second finance lease agreement
2026-12-15ASU 2024-03 is effective for fiscal years beginning after December 15, 2026
2027-12-15ASU 2024-03 is effective for interim periods beginning after December 15, 2027
2029-11Due date of third finance lease agreement

Keywords

financial results, biotech-nutraceutical, OEM/ODM, revenue, net income, DSwiss, financial statements

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.